300401.SHE Zhejiang Garden Bio-chemical High-tech Co Ltd
- Market cap
- CNY 6.63B
- P/E
- 30.4x
- P/B
- 1.78x
- ROE
- 6.2%
- Dividend yield
- 1.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300401.SHE undervalued?
Graham number300401.SHE trades 55.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Garden Bio-chemical High-tech Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Garden Bio-chemical High-tech Co Ltd yet.
Zhejiang Garden Bio-chemical High-tech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Garden Bio-chemical High-tech Co Ltd
Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China. The company offers lanolin cholesterol series products, such as cholesterol and feed grade cholesterol; vitamin D3 products, including food additives compound nutrient fortifier SDS, food additives compound nutritional fortifier CO and MO, cholecalciferol, vitamin D3 particles, feed additive vitamin D3 oil, and VD3 resin oil;…
Full company profileZhejiang Garden Bio-chemical High-tech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Garden Bio-chemical High-tech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 329M | 420M | 660M | 718M | 659M | 1.12B | 1.42B | 1.09B | 1.24B | 1.24B | 1.29B |
| Gross Profit | 111M | 232M | 437M | 497M | 378M | 766M | 931M | 653M | 724M | 688M | 554M |
| Operating Income | 44.3M | 151M | 356M | 399M | 286M | 586M | 436M | 207M | 355M | 383M | 295M |
| EBITDA | 70.6M | 185M | 373M | 414M | 280M | 490M | 458M | 303M | 471M | 563M | 285M |
| Net Income | 43.8M | 130M | 307M | 344M | 263M | 484M | 384M | 192M | 309M | 305M | 224M |
| EPS | 0.10 | 0.27 | 0.64 | 0.72 | 0.48 | 0.89 | 0.71 | 0.32 | 0.52 | 0.56 | 0.41 |
| Balance Sheet | |||||||||||
| Total Assets | 877M | 1.39B | 1.65B | 2.08B | 3.43B | 3.53B | 4.13B | 5.26B | 5.61B | 5.78B | 5.96B |
| Total Liabilities | 124M | 114M | 84.6M | 337M | 515M | 1.25B | 1.56B | 2.37B | 2.39B | 2.29B | 2.35B |
| Shareholders' Equity | 753M | 1.28B | 1.56B | 1.74B | 2.91B | 2.28B | 2.57B | 2.89B | 3.22B | 3.49B | 3.61B |
| Cash & Short-term Investments | 58.3M | 441M | 185M | 606M | 1.36B | 502M | 555M | 1.50B | 1.42B | 1.03B | 1.29B |
| Total Debt | 45.0M | 45.0M | - | 255M | 200M | 415M | 626M | 1.33B | 1.52B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 49.3M | 147M | 253M | 367M | 417M | 504M | 377M | 160M | 466M | 475M | - |
| Capital Expenditure | 60.5M | 71.6M | 218M | 446M | 579M | 707M | 380M | 245M | 480M | 362M | 337M |
| Free Cash Flow | -11.3M | 75.1M | 35.1M | -79.6M | -162M | -203M | -2.89M | -84.6M | -14.0M | 113M | 84.1M |
| Ratios | |||||||||||
| ROE | 5.8% | 10.2% | 19.7% | 19.7% | 9.0% | 21.2% | 14.9% | 6.6% | 9.6% | 8.7% | 6.2% |
| ROA | 5.0% | 9.3% | 18.7% | 16.5% | 7.7% | 13.7% | 9.3% | 3.7% | 5.5% | 5.3% | 3.8% |
| Net Profit Margin | 13.3% | 31.1% | 46.6% | 47.8% | 39.9% | 43.3% | 27.1% | 17.6% | 24.9% | 24.6% | 17.3% |
| Debt to Equity | 0.06x | 0.04x | - | 0.15x | 0.07x | 0.18x | 0.24x | 0.46x | 0.47x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Garden Bio-chemical High-tech Co Ltd dividends
- Dividend yield
- 1.39%
- Forward dividend
- 0.11 CNY
- Payout ratio
- 30.2%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 92.2M | 0.17 | 30.2% |
| 2024 | CNY 67.4M | 0.11 | 21.8% |
| 2023 | CNY 77.1M | 0.13 | 40.1% |
| 2022 | CNY 102M | 0.19 | 26.6% |
| 2021 | CNY 56.0M | 0.10 | 11.6% |
| 2020 | CNY 10.1M | 0.02 | 3.8% |
| 2019 | CNY 62.3M | 0.13 | 18.1% |
| 2018 | CNY 28.8M | 0.06 | 9.4% |
| 2017 | CNY 11.0M | 0.02 | 8.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2.5:1 on May 4, 2018.
Who owns Zhejiang Garden Bio-chemical High-tech Co Ltd
- Insiders 34.04%
- Institutions 9.16%
- Public & others 56.81%
- Shares outstanding 545M
- Free float 360M
Zhejiang Garden Bio-chemical High-tech Co Ltd company profile
- Company name
- Zhejiang Garden Bio-chemical High-tech Co Ltd
- Ticker
- 300401.SHE
- ISIN
- CNE100001XX7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,163
- Fiscal year end
- December
- Address
- No. 2, Huayuan Kangping Road, Dongyang, China, 322121
- Phone
- 86 571 8657 1191
- Website
- hybiotech.com
About Zhejiang Garden Bio-chemical High-tech Co Ltd
Zhejiang Garden Biopharmaceutical Co.,Ltd. engages in the research, development, production and sales of vitamin products and pharmaceuticals in China. The company offers lanolin cholesterol series products, such as cholesterol and feed grade cholesterol; vitamin D3 products, including food additives compound nutrient fortifier SDS, food additives compound nutritional fortifier CO and MO, cholecalciferol, vitamin D3 particles, feed additive vitamin D3 oil, and VD3 resin oil; and 25 HydroxyVitamin D3 Progen, 25 hydroxyvitamin D3, and 25 hydroxyvitamin D3 powder. It also provides refined lanolin comprising anhydrous lanolin, wool oil, wool wax, low chroma ultra pure fat, lanolin alcohol, isopropyl lanolate, lanolinic acid, high acid fat, and wool acid biofuel/wool alcohol biofuel; and vitamin D3 environmental rodenticide. Zhejiang Garden Biopharmaceutical Co.,Ltd. was formerly known as Zhejiang Garden Bio-chemical High-tech Co., Ltd. and changed its name to Zhejiang Garden Biopharmaceutical Co.,Ltd. in April 2023. Zhejiang Garden Biopharmaceutical Co.,Ltd. was founded in 2000 and is based in Dongyang, China.
Zhejiang Garden Bio-chemical High-tech Co Ltd management
7- Mr. Huanzheng MaVice Chairman & GM · born 1965
- Mr. Chunhua WuCFO & Financial Director · born 1976
- Mr. Quanheng YuVP, Secretary to the Board & Director · born 1966
- Mr. Xiao Ping LiuDeputy General Manager · born 1966
- Mr. Guoping QianDeputy General Manager · born 1977
- Mr. Jiangang LiuExecutive Deputy General Manager · born 1974
- Li Jin YaoAccounting Supervisor